Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:TEVA
- CUSIP: N/A
- Web: www.tevapharm.com
- Market Cap: $17.76984 billion
- Outstanding Shares: 1,016,000,000
- 50 Day Moving Avg: $27.91
- 200 Day Moving Avg: $31.10
- 52 Week Range: $16.81 - $53.96
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 4.36
- P/E Growth: -2.79
- Annual Revenue: $23.37 billion
- Price / Sales: 0.74
- Book Value: $23.99 per share
- Price / Book: 0.71
- Annual Dividend: $1.16
- Dividend Yield: 6.6%
- EBIDTA: $7.42 billion
- Net Margins: -25.18%
- Return on Equity: 15.96%
- Return on Assets: 5.31%
- Debt-to-Equity Ratio: 1.30%
- Current Ratio: 0.94%
- Quick Ratio: 0.61%
- Average Volume: 14.86 million shs.
- Beta: 0.46
- Short Ratio: 4.71
Frequently Asked Questions for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
What is Teva Pharmaceutical Industries Limited's stock symbol?
Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How often does Teva Pharmaceutical Industries Limited pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited announced a quarterly dividend on Monday, August 7th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share on Thursday, September 14th. This represents a $0.34 annualized dividend and a dividend yield of 1.99%. The ex-dividend date of this dividend is Friday, August 25th. View Teva Pharmaceutical Industries Limited's Dividend History.
How were Teva Pharmaceutical Industries Limited's earnings last quarter?
Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted its quarterly earnings results on Thursday, August, 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.06 by $0.07. The business earned $5.69 billion during the quarter, compared to analysts' expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.25 earnings per share. View Teva Pharmaceutical Industries Limited's Earnings History.
When will Teva Pharmaceutical Industries Limited make its next earnings announcement?
What guidance has Teva Pharmaceutical Industries Limited issued on next quarter's earnings?
Teva Pharmaceutical Industries Limited updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $4.30-4.50 for the period, compared to the Thomson Reuters consensus estimate of $4.73. The company issued revenue guidance of $22.8-23.2 billion, compared to the consensus revenue estimate of $23.43 billion.
Where is Teva Pharmaceutical Industries Limited's stock going? Where will Teva Pharmaceutical Industries Limited's stock price be in 2017?
25 analysts have issued 12 month price objectives for Teva Pharmaceutical Industries Limited's shares. Their forecasts range from $19.00 to $80.00. On average, they anticipate Teva Pharmaceutical Industries Limited's share price to reach $36.82 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Limited.
What are analysts saying about Teva Pharmaceutical Industries Limited stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Limited stock:
- 1. According to Zacks Investment Research, "Teva missed estimates for both earnings and sales in Q2. The company also slashed its 2017 earnings and sales outlook to reflect the challenging environment in the U.S. generics business and the continued deterioration in Venezuela. Teva also announced a 75% cut in its dividend. The U.S. generics industry’s competitive and pricing pressure is expected to continue in the near future. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products, a high cost base and debt load and the sudden departure of its CEO. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to the growth of the Generics unit. However, a clear path to growth is not visible." (8/9/2017)
- 2. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
- 3. Maxim Group analysts commented, "We reviewed and revised our model prior to the 1Q17 earnings release. Based on 2017 guidance and our expectations, we adjust OTC revenues in 1Q17 to $277M from $346M to reflect the change in foreign exchange rate as of December 1, 2016. Our estimate for total 2017 revenues is unchanged at $24B." (3/29/2017)
- 4. Royal Bank Of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)
Are investors shorting Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited saw a increase in short interest in July. As of July 31st, there was short interest totalling 45,907,938 shares, an increase of 16.9% from the July 14th total of 39,285,360 shares. Based on an average daily trading volume, of 4,970,113 shares, the short-interest ratio is currently 9.2 days.
Who are some of Teva Pharmaceutical Industries Limited's key competitors?
Some companies that are related to Teva Pharmaceutical Industries Limited include Shire PLC (SHP), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Akorn (AKRX), Taro Pharmaceutical Industries (TARO), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Horizon Pharma PLC (HZNP), Cambrex Corporation (CBM), Corcept Therapeutics Incorporated (CORT), Pacira Pharmaceuticals (PCRX), Emergent Biosolutions (EBS), Theravance Biopharma (TBPH) and Innoviva (INVA).
Who are Teva Pharmaceutical Industries Limited's key executives?
Teva Pharmaceutical Industries Limited's management team includes the folowing people:
- Sol J. Barer, Chairman of the Board
- Yitzhak Peterburg, Interim President and Chief Executive Officer
- Eyal Desheh, Group Executive Vice President, Chief Financial Officer
- Dipankar Bhattacharjee, President and Chief Executive Officer-Global Generic Medicines Group
- Carlo de Notaristefani, President and Chief Executive Officer-Global Operations
- Robert Koremans, President, Chief Executive Officer - Global Specialty Medicines
- Iris Beck-Codner, Group Executive Vice President - Corporate Marketing & Communication
- Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D
- Mark Sabag, Group Executive Vice President-Human Resources
- David M. Stark, Group Executive Vice President-Chief Legal Officer
Who owns Teva Pharmaceutical Industries Limited stock?
Teva Pharmaceutical Industries Limited's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (7.51%), Franklin Resources Inc. (6.57%), FMR LLC (4.22%), Bank of New York Mellon Corp (1.79%), Northern Cross LLC (1.75%) and Nordea Investment Management AB (1.27%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Limited.
Who sold Teva Pharmaceutical Industries Limited stock? Who is selling Teva Pharmaceutical Industries Limited stock?
Teva Pharmaceutical Industries Limited's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, FIL Ltd, Janus Henderson Group PLC, South Texas Money Management Ltd., Great West Life Assurance Co. Can, Banque Pictet & Cie SA, Commerzbank Aktiengesellschaft FI and Airain ltd. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.
Who bought Teva Pharmaceutical Industries Limited stock? Who is buying Teva Pharmaceutical Industries Limited stock?
Teva Pharmaceutical Industries Limited's stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Franklin Resources Inc., FMR LLC, Capital World Investors, Alliancebernstein L.P., Migdal Insurance & Financial Holdings Ltd., Northern Cross LLC and Polaris Capital Management LLC. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.
How do I buy Teva Pharmaceutical Industries Limited stock?
Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries Limited's stock price today?
MarketBeat Community Rating for Teva Pharmaceutical Industries Limited (NYSE TEVA)MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $17.10.
Consensus Ratings for Teva Pharmaceutical Industries Limited (NYSE:TEVA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 17 Hold Ratings, 7 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.24)|
|Consensus Price Target: ||$36.82 (115.33% upside)|
Analysts' Ratings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
(Data available from 8/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/16/2017||Citigroup Inc.||Downgrade||Buy -> Neutral||$32.00 -> $19.00||Medium|
|8/9/2017||Deutsche Bank AG||Reiterated Rating||Buy||$43.00 -> $28.00||High|
|8/9/2017||Jefferies Group LLC||Reiterated Rating||Hold||$33.00 -> $26.00||Medium|
|8/9/2017||Cantor Fitzgerald||Reiterated Rating||Neutral||$31.00 -> $27.00||High|
|8/9/2017||Credit Suisse Group||Reiterated Rating||Outperform||$39.00||High|
|8/7/2017||Barclays PLC||Lower Price Target||Equal Weight||$38.00 -> $23.00||High|
|8/4/2017||Piper Jaffray Companies||Reiterated Rating||Neutral||$28.00 -> $23.00||High|
|8/4/2017||Sanford C. Bernstein||Downgrade||Outperform -> Market Perform||$42.00 -> $28.00||High|
|8/4/2017||Maxim Group||Reiterated Rating||Hold||$35.00||High|
|8/4/2017||Cowen and Company||Downgrade||Outperform -> Market Perform||$50.00 -> $30.00||High|
|8/4/2017||Royal Bank Of Canada||Downgrade||Outperform -> Underperform||$37.00 -> $21.00||N/A|
|8/3/2017||CIBC||Reiterated Rating||Outperform -> Market Perform||High|
|8/3/2017||Oppenheimer Holdings, Inc.||Downgrade||Outperform -> Market Perform||$41.00||High|
|6/27/2017||Wells Fargo & Company||Reiterated Rating||Hold||N/A|
|4/6/2017||BTIG Research||Reiterated Rating||Neutral||Low|
|2/28/2017||Argus||Downgrade||Buy -> Hold||$59.35 -> $31.90||N/A|
|2/17/2017||J P Morgan Chase & Co||Set Price Target||Hold||$37.00||N/A|
|1/31/2017||Bank of America Corporation||Upgrade||Neutral -> Buy||N/A|
|12/4/2016||Morgan Stanley||Downgrade||Overweight -> Equal Weight||$63.00 -> $42.00||N/A|
|11/4/2016||HSBC Holdings plc||Downgrade||Buy -> Hold||$44.00 -> $66.00||N/A|
|10/7/2016||Leerink Swann||Set Price Target||Buy||$57.00||N/A|
|9/29/2016||OTR Global||Initiated Coverage||Positive||N/A|
|7/17/2016||Goldman Sachs Group, Inc. (The)||Lower Price Target||$70.00 -> $60.00||N/A|
|4/19/2016||Canaccord Genuity||Reiterated Rating||Buy||N/A|
|11/27/2015||Berenberg Bank||Lower Price Target||Hold||$72.00 -> $65.00||N/A|
Earnings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)Earnings History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/21/2017|| || || || || || || || |
|8/3/2017||6/30/2017||$1.06||$0.99||$5.72 billion||$5.69 billion||View||Listen|
|5/11/2017||Q1 17||$1.06||$1.06||$5.69 billion||$5.63 billion||View||N/A|
|2/13/2017||Q416||$1.36||$1.38||$6.26 billion||$6.25 billion||View||N/A|
|11/15/2016||Q316||$1.29||$1.31||$5.71 billion||$5.56 billion||View||N/A|
|8/4/2016||Q216||$1.20||$1.25||$4.86 billion||$5.00 billion||View||N/A|
|5/9/2016||Q116||$1.17||$1.20||$4.78 billion||$4.81 billion||View||N/A|
|2/11/2016||Q415||$1.29||$1.28||$4.83 billion||$4.88 billion||View||Listen|
|10/29/2015||Q315||$1.28||$1.35||$4.75 billion||$4.80 billion||View||Listen|
|7/30/2015||Q215||$1.31||$1.43||$4.90 billion||$4.97 billion||View||Listen|
|4/30/2015||Q115||$1.26||$1.36||$4.84 billion||$5.00 billion||View||N/A|
|2/5/2015||Q414||$1.31||$1.31||$5.17 billion||$5.17 billion||View||N/A|
|10/30/2014||Q314||$1.23||$1.32||$5.09 billion||$5.06 billion||View||N/A|
|7/31/2014||Q214||$1.21||$1.23||$5.08 billion||$5.00 billion||View||N/A|
|5/1/2014||Q114||$1.22||$1.22||$5.11 million||$5.00 billion||View||N/A|
|2/6/2014||Q413||$1.26||$1.42||$5.19 billion||$5.40 billion||View||N/A|
|10/31/2013||Q313||$1.26||$1.27||$5.00 billion||$5.06 billion||View||N/A|
|8/1/2013||Q213||$1.20||$1.20||$4.94 billion||$4.90 billion||View||N/A|
|5/2/2013||Q113||$1.10||$1.12||$4.85 billion||$4.90 billion||View||N/A|
|2/7/2013||Q412||$1.33||$1.32||$5.26 billion||$5.20 billion||View||N/A|
|11/1/2012||Q312||$1.25||$1.28||$5.08 billion||$5.00 billion||View||N/A|
Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.19 EPS
Next Year EPS Consensus Estimate: $3.92 EPS
Current Dividend Information for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
|Dividend Growth:||2.10% (3 Year Average)|
|Payout Ratio:||-18.95% (Trailing 12 Months of Earnings) |
27.68% (Based on This Year's Estimates)
29.59% (Based on Next Year's Estimates)
Dividend History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Latest Headlines for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TEVA) Chart for Friday, August, 18, 2017